Nimbus Synergies Appoints New Board Member Michael Ball to Enhance Leadership in Canadian Health Tech
Nimbus Synergies, investor, partner, and mentor to Canada’s most promising health technology companies, is pleased to announce the appointment of Michael Ball to the Board of Directors of Discovery Parks and Nimbus Synergies. Michael was also appointed to Nimbus’ Health Tech Investment Committee. Michael Ball is an industry veteran with over 30 years of global business experience leading and scaling innovative healthcare start-ups to exit through C-suite, board, and advisory roles.
“It is an exciting time to be a part of Canada’s flourishing health tech sector and I am thrilled to serve on the Board of an organization that is well-aligned to support the needs of this industry as an increasingly important constituent,” said Michael Ball.
Based in San Diego, Michael is the Founder and CEO of Marketech Solutions, a consultancy providing strategic expertise in the precision health, life sciences, genomics, and diagnostics industries. Prior to this, Michael was the CEO of Canexia Health, a clinical diagnostics company based out of Vancouver, BC, specializing in liquid biopsy testing for cancer patients. He also served as the Global VP of Informatics at Illumina, a $50B leader in the Genomics space, after his role as CEO at GenoLogics, a venture-backed startup that was acquired by Illumina in 2015. Michael also serves on the Board of the Canary Foundation, a non-profit that has raised over $64 million to support research aimed at creating reliable and affordable early detection tests for cancer, and is an active mentor for Creative Destruction Labs (CDL) – Vancouver.
“Michael’s expertise and leadership in health tech make him a welcomed addition to Nimbus’ Board to help guide us through our next phase of growth while providing mentorship to our current portfolio companies,” said Paul Geyer, CEO of Discovery Parks & Nimbus Synergies. “I look forward to his insights and contributions moving forward as we enhance our value to our key stakeholders.”
Michael’s appointment coincides with long-time life sciences champion and leader David Main’s retirement from Nimbus’ Board, where he served for the past five years. Through his advocacy of health tech, David was instrumental in the ideation, creation, and early traction of Nimbus. He also served on the Board of Nimbus’ parent organization, Discovery Parks, for more than two decades. David remains committed to Nimbus’ continued success and is joining the Board of Nimbus investee HeadCheck Health, where he will support the company’s vision of protecting athletes from mismanaged head injuries. In addition, David remains the CEO of Notch Therapeutics Inc., a rapidly growing venture-backed biotechnology company.
“David’s impact and contributions to our organization over the decades cannot be overemphasized – he has been a dedicated steward of Discovery Parks’ mission to see technology become the most economically important sector in British Columbia,” reflected Paul Geyer. “We look forward to working closely with David in his new capacity and wish him the greatest success and fulfillment in his future endeavours.”
ABOUT NIMBUS SYNERGIES
Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the health technology sector through its leadership as investor, partner, and mentor.
Follow Nimbus Synergies on LinkedIn (https://www.linkedin.com/company/nimbus-synergies) and Twitter @nimbussynergies
Original source here.